We believe it is important you fish in your own antibody “pond” when selecting therapeutic leads in order to avoid the possibility of inadvertently developing an antibody already selected by a competitor. The dangers of fishing in the same pond are briefly outlined in a tale of two patents.
Exclusive Antibody Libraries
In 1997 and 2003, before the days of next generation sequencing, two companies filed patents on identical antibodies against the same target selected from the same (or similar) natural phage antibody library. An interference was decided in favor of the company that filed earlier. We have found that the widespread use of next generation sequencing has only exacerbated this problem.
Each library Specifica provides to its partners is exclusive to that partner, created from unique donor sets not used for any other library. Each library is constructed de novo.
In the case of Generation 2 Libraries, the unique donor sets provide the rearranged variable genes, while in the case of Generation 3 Libraries, each comprises a unique combination of naturally replicated CDRs, combined with at least 100 million unique HCDR3s derived from your unique donor pool, guaranteeing each supplied Generation 3 Library Platform is one of a kind.